Sulfated non-anticoagulant low molecular weight heparin in the prevention of cancer and non-cancer associated thrombosis without compromising hemostasis

摘要: Abstract Introduction Cancer-associated thrombosis (CAT) accounts for about 20% of all cases Venous Thromboembolism (VTE). Tissue factor (TF) is documented to be highly expressed on cancer cells and pathological angiogenic endothelial cells. Here, we used a novel oxidized sulfated ultra-LMWH, S-NACH, which devoid anti-factor Xa IIa activities with limited no systemic anticoagulant effects. This form has enhanced binding vascular (EC) releases potentiates the action tissue pathway inhibitor (TFPI). S-NACH binds high affinity EC, EC TFPI, promotes antithrombotic effect risk bleeding complications. Materials methods We investigated effects clot kinetics in vitro vivo. Also, CAT mediated by human acute leukemia (K562) pancreatic (SUIT2). Results was associated ~3-fold increase TFPI 2 levels within 3 h. reversed hypercoagulability state that vitro. In vivo, at 20 mg/kg subcutaneously (SC) had time compared both tinzaparin enoxaparin 5 mg/kg SC. did not show any anti-IIa or anti-Xa comparison (p  Conclusion Data suggest importance through its binding, release interaction enhancing activity prevention non-cancer